A Rare Case of COVID-19 Vaccination-Induced Cholangiopathic Liver Injury

Sobaan Taj; Harshavardhan Sanekommu; Anmol Johal; Jayasree Ravilla; Steven Imburgio; Sowmya Dandu; Apurva Vedire; Brett Miller; Mohammad Hossain

doi:10.14309/crj.0000000000001079

A Rare Case of COVID-19 Vaccination-Induced Cholangiopathic Liver Injury

ACG Case Rep J. 2023 Jun 14;10(6):e01079. doi: 10.14309/crj.0000000000001079. eCollection 2023 Jun.

Authors

Sobaan Taj¹, Harshavardhan Sanekommu¹, Anmol Johal¹, Jayasree Ravilla², Steven Imburgio¹, Sowmya Dandu¹, Apurva Vedire¹, Brett Miller¹, Mohammad Hossain¹

Affiliations

¹ Department of Medicine, Jersey Shore University Medical Center, Neptune City, NJ.
² Department of Medicine, Monmouth Medical Center, Avenue Long Branch, NJ.

Abstract

Drug-induced liver injury is a serious adverse drug reaction that can result in acute liver injury or cholestatic injury affecting the bile ducts, known as cholangiopathic liver injury (CLI). Although CLI is not as familiar as the hepatocellular pattern, emerging evidence suggests that it may occur after coronavirus disease 2019 (COVID-19) vaccination. This case report focuses on an 89-year-old woman who developed CLI after receiving the tozinameran COVID-19 vaccine. The main aim of this report was to raise awareness of the possibility of developing CLI after COVID-19 vaccination and to underscore the critical significance of promptly identifying and managing this infrequent but severe side effect.

Keywords: COVID 19; DILI; cholangiopathic injury; vaccination.

Publication types

Case Reports